| Document |
Document Title |
|
WO/2023/156461A1 |
The present invention relates to the field of the synthesis of chemical compounds having a dihydrobenzoxepine structure. In particular, the invention relates to a process for preparing chemical compounds comprising a 2,5-dihydro-1-benzox...
|
|
WO/2023/110132A1 |
The invention is in the field of fragrances and relates to novel oxa-macrocyclic fragrance compounds according to general formula (I) with a musk-based note and improved biological degradability and further with improved chemical stabili...
|
|
WO/2023/067043A9 |
Improved methods of making amberketal and amberketal homologues and compositions comprising same, improved squalene-hopene cyclase (SHC) enzymes to be used in said methods, nucleic acid constructs and vectors encoding said enzymes, and h...
|
|
WO/2023/089158A1 |
Disclosed are oxa macrocyclic ketones of formula (I) possessing musky, powdery, nitro musk odor characteristics.
|
|
WO/2023/067044A1 |
The disclosure relates to sesquiterpene homologues, their use as fragrance and a method of their production.
|
|
WO/2023/038093A1 |
Provided is a deuterium-enriched composition comprising a deuterium-substituted carboxylic acid or a salt thereof, wherein the carboxylic acid or the salt thereof includes an α hydrogen of a carboxy group and a hydrogen other than the Î...
|
|
WO/2023/027336A1 |
The present specification relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting device comprising same.
|
|
WO/2023/026884A1 |
To provide a curable composition that generates little outgas from an obtained cured product. The curable composition includes a radical polymerization initiator represented by formula 1 and a radical polymerizable compound. In formula 1...
|
|
WO/2023/026051A1 |
Methods for staining mitochondria are disclosed involving using a composition containing a cationic species of the formula: (I) wherein at least one of Y and Z is a substituted or unsubstituted azetidine group; X is selected from O, S, S...
|
|
WO/2023/001323A1 |
The present invention relates to a lipidoid of general formula I, wherein X is selected from -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C≡...
|
|
WO/2022/263702A1 |
Pladienolide B for use in the treatment of glioblastoma.
|
|
WO/2022/243300A1 |
The present invention concerns a composition of matter comprising a) 0.5 to 98.8% w/w of (Z)-oxacyclohexadec- 12-en-2-one; b) 0.1 to 10% w/w of (E)-oxacyclohexadec-12-en-2-one; c) 0 to 10% w/w of (E)-oxacyclohexadec-13-en-2-one; and d) 0...
|
|
WO/2022/217265A1 |
Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., R1, R2, X1, X2, Y1, Y2, Y3, Y4, Y5, Y6, Y7, and Y8) are as disclosed herein. Also provided herein are ph...
|
|
WO/2022/207923A1 |
Substituted lactones and the polymers prepared by ring opening thereof are disclosed, likewise the processes for producing the lactones and polymers and the use thereof, in particular in electrochemical applications, in particular in ele...
|
|
WO/2022/191314A1 |
The present invention makes it possible to produce adipic acid at a high selectivity without emitting dinitrogen monoxide by using a 3-hydroxyadipic acid 3,6-lactone composition as a starting material, the composition containing 3 to 30 ...
|
|
WO/2022/192384A1 |
Provided herein are biosynthetic methods for producing lactones, such as macrocyclic lactones, from fatty acids. The lactones produced using and/or during the biosynthetic methods are also provided.
|
|
WO/2022/179476A1 |
Disclosed in the present invention are a series of fused polycyclic substituted 5-carboxylic acid thienopyrimidine dione compounds and the use thereof. Specifically disclosed are a compound represented by formula (II) and a pharmaceutica...
|
|
WO/2022/162471A1 |
Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
|
|
WO/2022/165398A1 |
In alternative embodiments, provided are methods for treating and ameliorating a cancer, or recurrence of a cancer such as acute myeloid leukemia (AML) comprising administration to an individual in need thereof a pharmaceutical compositi...
|
|
WO/2022/134297A1 |
The present invention relates to a preparation method for a carboxylate ester compound, comprising: under the catalysis of a nitrite ester, reacting carboxylic acid and methanol in air, so as to obtain an ester compound. The preparation ...
|
|
WO/2022/133031A1 |
This disclosure relates generally to inhibitors of MHC-I downmodulation, and methods of treating or preventing an HIV infection by administering the inhibitors to a patient in need of treatment thereof.
|
|
WO/2022/040788A1 |
Anti -cancer, chemotherapeutic, or antiproliferative compositions comprising, as an active ingredient, a compound of formula (I0), or a salt, or prodrug thereof: and an anti-cancer, chemotherapeutic, or antiproliferative compound (A) or ...
|
|
WO/2021/249008A1 |
Disclosed in the present invention is a method for preparing epsilon-caprolactone by using an in-situ peroxide. The method efficiently utilizes an in-situ peroxide obtained in a process of oxidizing alcohol by oxygen to oxidize cyclohexa...
|
|
WO/2021/209482A1 |
An enzyme-mediated method for the production of Amberketal and Amberketal homologues, the products of said method, and uses of said products.
|
|
WO/2021/208918A1 |
Provided are a class of compounds, represented by formula (I"'), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds ...
|
|
WO/2021/188772A1 |
The present disclosure describes, in part, compositions and methods for treating pathologic pains associated with malignant growth disorders by administering a therapeutically effective amount of a K+/Cl- cotransporter (Kcc2/KCC2) gene e...
|
|
WO/2021/122945A1 |
The present invention concerns a composition of matter comprising a) 0.5 to 85% w/w of (Z)-oxacyclohexadec-12-en-2-one; b) 0.5 to 30% w/w of (E)-oxacyclohexadec-12-en-2-one; c) 0 to 30% w/w of (E)-oxacyclohexadec-13-en-2-one; and d) 0.5 ...
|
|
WO/2021/103798A1 |
Disclosed is a method for preparing a lactone compound, the method comprising performing an oxidation reaction on a cyclic ketone using molecular oxygen in the presence of an organic nitrogen-oxygen radical precursor, a free radical init...
|
|
WO/2021/104529A1 |
The present disclosure relates to the field of pharmaceutical chemistry, and specifically relates to a use of a brefeldin A ester derivative in inhibiting tumor proliferation activity, the structure of said brefeldin A ester derivative b...
|
|
WO/2021/047292A1 |
Disclosed in the present invention is a novel method for co-production of a high-efficiency carboxylic acid based on oxygen oxidation and ε-caprolactone, i.e., under the catalysis of a catalyst, oxidizing cyclohexanone to ε-caprolacton...
|
|
WO/2021/037806A1 |
The presently claimed invention is directed to 2,2,6-trimethyl-4,5-dihydro-3H-oxepine and its use to impart an aroma impression to a composition. The presently claimed invention also relates to a method of imparting such an aroma impress...
|
|
WO/2021/038292A1 |
Compounds that are inhibitors of p38alpha and centrally available are described.
|
|
WO/2020/254507A1 |
Compounds of general Formula (I) wherein the elements A, L, R1 and R2 have a defined meaning, and their medical and non-medical use.
|
|
WO/2020/193681A1 |
The present invention relates to derivatives of 10-methylene lipids, their preparation and their use.
|
|
WO/2020/185712A1 |
The present disclosure relates to methods of alleviating a symptom of, treating, or preventing a sleep disorder by administering a ligand of α2δ-1 auxiliary subunit of voltage-gated calcium channels, a ligand of α2δ-2 auxiliary subun...
|
|
WO/2020/090700A1 |
The present invention addresses the problem of providing an ynone compound useful for the inducement of an endoplasmic reticulum stress response. The problem can be solved by an ynone compound represented by formula (1) [in the formula, ...
|
|
WO/2020/084005A1 |
The present invention relates to compounds binding to calreticulin which selectively inhibit growth of CALR mutant cells and/or exhibit selective cytotoxicity towards CALR mutant cells, to pharmaceutical compositions comprising such comp...
|
|
WO/2020/063999A1 |
Disclose herein are mono halogen or methyl-substituted 5-HT 2B antagonist compounds, which have been found with increased binding activity to 5-HT 2B receptor due to the substitution of halogen or methyl, and the method of using the comp...
|
|
WO/2020/055113A1 |
The present disclosure relates to an organic electroluminescent compound represented by formula 1 and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosu...
|
|
WO/2020/023356A1 |
The present invention provides compounds of formula (I) wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of prolif...
|
|
WO/2019/232639A1 |
The present invention provides a new compound of formula (II), extracted from Chaetomorpha Cannabina seaweed. (II) The methods for extraction from the seaweed, the fractionation and isolation of the compound, the determination of the ste...
|
|
WO/2019/207246A1 |
The present invention relates to a method for olefin metathesis, which comprises placing in contact: - at least one olefin, - at least one metathesis catalyst selected from the ruthenium alkylidene complexes comprising two imidazoline-2-...
|
|
WO/2019/200100A1 |
The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, ...
|
|
WO/2019/199667A2 |
The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, pa...
|
|
WO/2019/171278A1 |
The present invention is directed to heterocycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and / or GPR40 receptors. 5 More particul...
|
|
WO/2019/158485A1 |
The invention provides a method for synthesizing musk macrocycles comprising contacting an easily accessible diene starting materials bearing a Z-olefin moiety and performing a ring closing metathesis reaction in the presence of a Group ...
|
|
WO/2019/144132A1 |
Described herein are compounds that are estrogen receptor modulators of formula I' Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen rece...
|
|
WO/2019/124523A1 |
In the present invention, an efficacious therapy for glaucoma is discovered and provided as a medicine. A combination of the present invention, in particular a combination of 2-propanyl 4-{(3S, 5aR, 6R, 7R, 8aS)-6-[(1E, 3R)-4-(2, 5-diflu...
|
|
WO/2019/113019A2 |
This invention relates generally to the synthesis of E-macrocycles using stereoretentive ruthenium olefin metathesis catalysts supported by dithioiate ligands. Macrocycles were generated with excellent selectivity (>99% E) and in moderat...
|
|
WO/2019/104850A1 |
Disclosed is a method for preparing a lactone compound, for which a cyclic ketone compound serves as a raw material; in an oxygen-containing atmosphere, a cyclic organic nitroxide free radical serves as a catalyst, and a certain amount o...
|
